Introduction: Cardiovascular disease (CVD) is the leading cause of death worldwide.
Squalene (SQ), an intermediate for the cholesterol biosynthesis, has been proposed to act …

Anthracyclines are commonly used anticancer drugs with well-known and extensively
studied cardiotoxic effects in humans. In the clinical setting guidelines for assessing …

Doxorubicin (DOXO), a potent and widely used chemotherapeutic agent, causes irreversible
heart failure by increasing oxidative stress, which limits its clinical utility. Nuclear factor …

In the present study, we investigated the cardioprotective effects of coenzyme Q10 (Q10)
against doxorubicin (DOXO) induced cardiomyopathy. Twenty adult rats were distributed in …

Vinblastine (VBL) has been considered as a first-line anti-tumor drug for many years.
However, vinblastine-caused myocardial damage has been continually reported. The …

The use of Doxorubicin (DOXO), a potent antineoplastic agent, is limited by the development
of cardiotoxicity. DOXO-induced cardiotoxicity is multifactorial, although alterations in …

Doxorubicin (DOX) is considered as a backbone in several chemotherapeutic regimens.
Nevertheless, the reported systemic toxicity usually hampers its broad application …

The cardiotoxicity induced by doxorubicin is dose-dependent. The present study tested the
potential cardioprotective effect of Poly ADP Ribose Polymerase (PARP) pathway inhibitor …

Background Lingguizhugan decoction (LGZG), an ancient Chinese herbal formula, has
been used to treat cardiovascular diseases in eastern Asia. We investigated whether LGZG …

The clinical use of doxorubicin as a potent chemotherapeutic agent is limited due to its
dosedependent cardiotoxicity. Oxidative stress and inflammatory pathways have a pivotal …